124 related articles for article (PubMed ID: 15100647)
41. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
Lee CY; Bu LX; Rennie PS; Jia WW
Cancer Gene Ther; 2007 Jul; 14(7):652-60. PubMed ID: 17479106
[TBL] [Abstract][Full Text] [Related]
42. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
43. Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer.
Nakamori M; Fu X; Pettaway CA; Zhang X
Prostate; 2004 Jun; 60(1):53-60. PubMed ID: 15129429
[TBL] [Abstract][Full Text] [Related]
44. Enhanced antiglioma activity of chimeric HCMV/HSV-1 oncolytic viruses.
Shah AC; Parker JN; Gillespie GY; Lakeman FD; Meleth S; Markert JM; Cassady KA
Gene Ther; 2007 Jul; 14(13):1045-54. PubMed ID: 17429445
[TBL] [Abstract][Full Text] [Related]
45. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.
Mezhir JJ; Advani SJ; Smith KD; Darga TE; Poon AP; Schmidt H; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2005 Oct; 65(20):9479-84. PubMed ID: 16230412
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the antitumor effects of Herpes simplex virus lacking ribonucleotide reductase in a murine retinoblastoma model.
Cullinan AE; Lindstrom MJ; Sabet S; Albert DM; Brandt CR
Curr Eye Res; 2004; 29(2-3):167-72. PubMed ID: 15512963
[TBL] [Abstract][Full Text] [Related]
47. Combination of mutated herpes simplex virus type 1 (G207 virus) with radiation for the treatment of squamous cell carcinoma of the head and neck.
Kim SH; Wong RJ; Kooby DA; Carew JF; Adusumilli PS; Patel SG; Shah JP; Fong Y
Eur J Cancer; 2005 Jan; 41(2):313-22. PubMed ID: 15661558
[TBL] [Abstract][Full Text] [Related]
48. Establishment of a novel foreign gene delivery system combining an HSV amplicon with an attenuated replication-competent virus, HSV-1 HF10.
Zhang L; Daikoku T; Ohtake K; Ohtsuka J; Nawa A; Kudoh A; Iwahori S; Isomura H; Nishiyama Y; Tsurumi T
J Virol Methods; 2006 Nov; 137(2):177-83. PubMed ID: 16854473
[TBL] [Abstract][Full Text] [Related]
49. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
[TBL] [Abstract][Full Text] [Related]
50. Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.
Reisoli E; Gambini E; Appolloni I; Gatta V; Barilari M; Menotti L; Malatesta P
Cancer Gene Ther; 2012 Nov; 19(11):788-95. PubMed ID: 22996742
[TBL] [Abstract][Full Text] [Related]
51. Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
Zibert A; Thomassen A; Müller L; Nguyen L; Glouchkova L; Fraefel C; Roskrow M; Meisel R; Dilloo D
Gene Ther; 2005 Dec; 12(23):1707-17. PubMed ID: 16034459
[TBL] [Abstract][Full Text] [Related]
52. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.
Ganesh S; Gonzalez Edick M; Idamakanti N; Abramova M; Vanroey M; Robinson M; Yun CO; Jooss K
Cancer Res; 2007 May; 67(9):4399-407. PubMed ID: 17483354
[TBL] [Abstract][Full Text] [Related]
53. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
54. Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.
Petrovic B; Leoni V; Gatta V; Zaghini A; Vannini A; Campadelli-Fiume G
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263257
[TBL] [Abstract][Full Text] [Related]
55. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model.
Toyoda H; Yin J; Mueller S; Wimmer E; Cello J
Cancer Res; 2007 Mar; 67(6):2857-64. PubMed ID: 17363609
[TBL] [Abstract][Full Text] [Related]
56. Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer.
Kimata H; Imai T; Kikumori T; Teshigahara O; Nagasaka T; Goshima F; Nishiyama Y; Nakao A
Ann Surg Oncol; 2006 Aug; 13(8):1078-84. PubMed ID: 16865590
[TBL] [Abstract][Full Text] [Related]
57. Oncolytic herpesvirus with secretable angiostatic proteins in the treatment of human lung cancer cells.
Yang CT; Lin YC; Lin CL; Lu J; Bu X; Tsai YH; Jia WW
Anticancer Res; 2005; 25(3B):2049-54. PubMed ID: 16158944
[TBL] [Abstract][Full Text] [Related]
58. Calcium depletion enhances nectin-1 expression and herpes oncolytic therapy of squamous cell carcinoma.
Yu Z; Li S; Huang YY; Fong Y; Wong RJ
Cancer Gene Ther; 2007 Aug; 14(8):738-47. PubMed ID: 17525764
[TBL] [Abstract][Full Text] [Related]
59. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
[TBL] [Abstract][Full Text] [Related]
60. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]